- Home
- XP vs MRNA Comparison
XP vs MRNA Comparison
Compare XP & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | MRNA |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.5B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | XP | MRNA |
|---|---|---|
| Price | $20.25 | $49.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 12 |
| Target Price | $22.67 | ★ $33.00 |
| AVG Volume (30 Days) | 6.4M | ★ 9.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $19.44 | $6.38 |
| Revenue Next Year | $13.81 | $12.33 |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $12.20 | $22.28 |
| 52 Week High | $23.13 | $55.20 |
Technical Indicators
Market Signals| Indicator | XP | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 61.47 |
| Support Level | $18.05 | $23.74 |
| Resistance Level | $20.37 | $55.20 |
| Average True Range (ATR) | 1.14 | 3.22 |
| MACD | -0.09 | 0.31 |
| Stochastic Oscillator | 35.46 | 72.78 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.